BiotechTube

topiramate; almotriptan malate

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Migraine

Conditions

Migraine, Classic Migraine, Common Migraine

Trial Timeline

Jun 1, 2005 → Jun 1, 2007

NCT ID
NCT00210496

About topiramate; almotriptan malate

topiramate; almotriptan malate is a approved stage product being developed by Johnson & Johnson for Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT00210496. Target conditions include Migraine, Classic Migraine, Common Migraine.

What happened to similar drugs?

20 of 20 similar drugs in Migraine were approved

Approved (20) Terminated (1) Active (0)
✅Galcanezumab + ErenumabEli LillyApproved
✅Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
✅Emgality 120 MG in 1 ML Prefilled SyringeEli LillyApproved
✅tramadol HCl/acetaminophenJohnson & JohnsonApproved
✅Ubrogepant 50 MG [Ubrelvy] + Ubrogepant 100 MG [Ubrelvy]AbbVieApproved
✅Atogepant 60 mg + Propranolol 160 mg + Topiramate 100 mgAbbVieApproved
✅Atogepant + UbrogepantAbbVieApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00210496ApprovedCompleted

Competing Products

20 competing products in Migraine

See all competitors
ProductCompanyStageHype Score
DFN-11Dr. Reddy's LaboratoriesPhase 2
32
DFN-15 ActiveDr. Reddy's LaboratoriesPhase 3
37
DFN-15 (fasted) + DFN-15 (fed) + Comparator Celebrex® (fed)Dr. Reddy's LaboratoriesPhase 1
26
DFN-11Dr. Reddy's LaboratoriesPhase 3
37
DFN-02Dr. Reddy's LaboratoriesPhase 3
37
DFN-15 Dose A (treatment A) + DFN-15 Dose B (treatment B)Dr. Reddy's LaboratoriesPhase 2
32
DFN-15Dr. Reddy's LaboratoriesPhase 2
32
ABP-450AEON BiopharmaPhase 2
17
Lasmiditan + PlaceboEli LillyPhase 3
40
Placebo + LY2300559Eli LillyPhase 2
27
lasmiditan 200 mg + Sumatriptan + matching placeboEli LillyPhase 1
29
ABP-450 + PlaceboAEON BiopharmaPhase 2
25
Lasmiditan + PlaceboEli LillyPhase 2
35
Ketorolac + Prochlorperazine + DiphenhydramineAssertio HoldingsPhase 2
17
Galcanezumab + ErenumabEli LillyApproved
43
Aricept (donepezil hydrochloride)EisaiPhase 2
35
E2007EisaiPhase 2
35
Galcanezumab + Rimegepant + Placebo + PlaceboEli LillyApproved
43
Galcanezumab + PlaceboEli LillyPhase 3
40
Lasmiditan + PlaceboEli LillyPhase 2
35